Mad in America: Rethinking Mental Health
Health & Fitness:Mental Health
Welcome to MIA Reports, showcasing our independent and original journalism devoted to rethinking psychiatry. We take selected MIA Reports and provide them as audio articles. Click here for the text version of this and all of our MIA reports.
The Whistleblower and Penn: A Final Accounting of Study 352
Written by Peter Simons, read by James Moore, first published on Mad in America, December 29, 2019.
Although the general story of ghostwriting in trials of psychiatric drugs is now pretty well known, the details of the corruption in specific trials are still emerging into the public record, often a decade or more after the original sin of fraudulent publication. The latest study to finally see the full light of day is GlaxoSmithKline’s study 352.
Perhaps the most infamous ghostwritten study is GSK’s study 329, which, in a 2001 report published in the American Journal of Psychiatry, falsely touted paroxetine (Paxil) as an effective treatment for adolescent depression. The company paid over $3 billion in penalties for fraud.
That same year, study 352 made its first appearance in the research literature. That was when Charles Nemeroff, who in the years ahead would become the public face of research misconduct, “authored” an article on the efficacy of paroxetine for bipolar disorder. It has taken 18 years for the full story of that corruption to become known, the final chapter recently emerging when a large cache of study 352 documents—emails, memos, and other internal correspondence between the key players—was made public.
The documents reveal a web of corruption that went beyond the fraud of ghostwriting into the spinning of negative results into positive conclusions, and the abetting of that corruption by an editor of the scientific journal that published the article. The documents also reveal a whitewashing of the corruption by the University of Pennsylvania.
However, it was the publication of these documents that provided Jay Amsterdam, an investigator in the trial who turned whistleblower after he smelled a rat, with a chance to say “case closed.” Amsterdam and Leemon McHenry have now published two articles that provide a step-by-step deconstruction of the study—the ghostwriting, the spinning of results, the betrayal of public trust.
Here is the story of that whistleblowing.
Jim Wright - World Benzodiazepine Awareness Day 2020
Angela Peacock - Medicating Normal
Awais Aftab - Bridging Critical and Conceptual Psychiatry
John Read and Irving Kirsch – Electroconvulsive Therapy (ECT) Does the Evidence From Clinical Trials Justify its Continued Use?
Scott Greenspan - Exercise for Youth Mental Health in the Lockdown
Dainius Pūras - Bringing Human Rights to Mental Health Care
Sunil Bhatia - When Psychology Speaks for You, Without You
Nicole Beurkens – What If This Pandemic Is the Best Thing to Happen to Children with Challenges?
MIA Town Hall 1 - Are We Living in the Most Dialogical Time Ever?
Sam Himelstein - The Impact of COVID-19 and Social Distancing on Adolescents
Ian Puppe - Where Western Medicine Meets Indigenous Healing
Mab Segrest - Narrating Asylum History Through an Anti-Racist Lens
Paula Caplan - Listen to a Veteran
MIA Report - Medication-Free Treatment in Norway - A Private Hospital Takes Center Stage
Ian Parker - Psychology is Not What You Think
Beatrice Birch - Inner Fire and Soul Health
Laysha Ostrow - Live and Learn
Peter Statsny - Reimagining Psychiatry
Sarah Kamens and Peter Kinderman - Moving Mental Health Work Away From Diagnosis
David Joslin – Remedy Alpine, Giving Veterans the Power to Seek Personal Discovery
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Mental Health Insights
MQ Open Mind
Speaking of Suicide
The Suicide Prevention Movement
Depression Talks Podcast